HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jmg.2007.056127v1 jmg.2007.056127v2 45/5/298    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Saggar, S Articles by Celebi, J T PubMed PubMed Citation Articles by Saggar, S Articles by Celebi, J T

CYLD mutations in familial skin appendage tumours

¹ Department of Dermatology, Columbia University, New York, USA
² Hadassah-Hebrew University Medical Center, Jerusalem, Israel
³ Department of Pathology, University of Nebraska Medical Center, Omaha, Nebraska, USA
⁴ Clinical Genetics Unit, Instituto da Crianca, Sao Paulo, Brazil
⁵ Department of Dermatology, Hospital das Clinicas, University of São Paulo, Brazil
⁶ Department of Dermatology, University of Cologne, Cologne, Germany

Correspondence to:
Dr J T Celebi, Department of Dermatology, Columbia University, Irving Cancer Research Center, 1130 St Nicholas Avenue, Room 312, New York, NY 10032, USA; jt165{at}columbia.edu]

ABSTRACT
Background: Germ-line mutations in CYLD are found in patients with familial skin appendage tumours. The protein product functions as a deubiquitinase enzyme, which negatively regulates NF-B and c-Jun N-terminal kinase signalling. Brooke–Spiegler syndrome (BSS) is characterised by cylindromas, trichoepitheliomas and spiradenomas, whereas in familial cylindromatosis (FC) patients present with cylindromas and in multiple familial trichoepitheliomas (MFT) with trichoepitheliomas as the only skin tumour type. Although described as distinct entities, recent studies suggest that they are within the spectrum of a single entity.

Objective: To investigate the mutation spectrum of CYLD and possible genotype–phenotype correlations.

Methods: 25 families including 13 BSS, 3 FC, and 9 MFT families were examined and evaluated for mutations in the CYLD gene.

Results: In total, 18 mutations in CYLD, including 6 novel mutations, were identified in 25 probands (72%). The mutation frequencies among distinct phenotypes were 85% for BSS, 100% for FC, and 44% for MFT. The majority of the mutations were insertions, deletions or nonsense mutations leading to formation of truncated proteins. All mutations were located between exons 9 to 20, encoding the NEMO binding site and the catalytic domain. Genotype–phenotype analysis failed to reveal a correlation between the types of mutations and their location within the gene and the patients’ phenotypes and disease severity.

Conclusions: This study provides further evidence on the role of CYLD in the pathogenesis of skin appendage tumours characterised by cylindromas, trichoepitheliomas and/or spiradenomas, but the molecular mechanisms of CYLD in skin tumorigenesis and the reasons for phenotypic variability remain to be explored.